Doxorubicin-Induced CardiomyopathySymptoms, Doctors, Treatments, Advances & More
Doxorubicin-Induced Cardiomyopathy Overview
Learn About Doxorubicin-Induced Cardiomyopathy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Beth Israel Deaconess HealthCare - Medical Care Ctr Lexington
Aarti Asnani is a primary care provider, practicing in Internal Medicine in Lexington, Massachusetts. She has been practicing medicine for over 18 years. Dr. Asnani is rated as an Elite provider by MediFind in the treatment of Doxorubicin-Induced Cardiomyopathy. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Doxorubicin-Induced Cardiomyopathy, Cardiomyopathy Due to Anthracyclines, Myocarditis, Cardiomyopathy, and Pacemaker Implantation. Dr. Asnani is board certified in American Board Of Internal Medicine. Dr. Asnani is currently accepting new patients.
Pawan Singal practices practicing medicine in Winnipeg, Canada. Mr. Singal is rated as an Elite expert by MediFind in the treatment of Doxorubicin-Induced Cardiomyopathy. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Doxorubicin-Induced Cardiomyopathy, Cardiomyopathy Due to Anthracyclines, Cardiomyopathy, and Heart Failure.
Ashim Bagchi practices practicing medicine in Winnipeg, Canada. Mr. Bagchi is rated as an Elite expert by MediFind in the treatment of Doxorubicin-Induced Cardiomyopathy. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Doxorubicin-Induced Cardiomyopathy, Cardiomyopathy Due to Anthracyclines, Cardiomyopathy, and Necrosis.
Summary: This is a randomized controlled clinical trial that aims to evaluate the safety and efficacy of Dapagliflozin as a cardioprotective in doxorubicin-induced cardiotoxicity in breast cancer patients.
Summary: Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity. Thereby patients treated for this malignancy are at double the risk of developing symptomatic heart failure / cardiomyopathy when compared to the general population. This corr...
